Aggressive chemo plus stem cell transplant tested for breast cancer

NCT ID NCT00186641

Completed Disease control Sponsor: Stanford University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This completed Phase 2 trial tested whether high-dose chemotherapy followed by a stem cell transplant could help people with breast cancer that responds to standard chemo. 203 patients with stage II, III, or IV breast cancer took part. The main goal was to see how long they survived.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: high-dose chemotherapy and stem cell transplant
What this could lead to: If successful, this approach could improve survival for patients with chemosensitive breast cancer.
What could go wrong: This is an older, completed Phase 2 trial with no reported results. High-dose chemotherapy carries serious risks, and the approach has not become standard for breast cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer graft versus host disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GRAFT VS HOST DISEASE

Contacts and locations

Locations

Stanford University Cancer Center

Stanford, California, 94305, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.